Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID DTD0020 Transporter Info
Gene Name SLC10A2
Transporter Name Apical sodium-dependent bile acid transporter
Gene ID
6555
UniProt ID
Q12908
Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)

Approved Drug

  Chenodeoxycholic acid

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Chenodeoxycholic acid inhibits the transportation of Sodium taurocholate by SLC10A2 (Ki = 75 microM) [1]

Affected Drug/Substrate

 Sodium taurocholate Modulation Type Inhibition

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)1-ASBT

  DT Modulation 2

 Chenodiol inhibits the transportation of Sodium taurocholate by SLC10A2 (Ki = 3.3 microM) [1]

Affected Drug/Substrate

 Sodium taurocholate Modulation Type Inhibition

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)1-ASBT

  Cyclosporine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cyclosporine inhibits the transportation of Sodium taurocholate by SLC10A2 (Ki = 24 microM) [1]

Affected Drug/Substrate

 Sodium taurocholate Modulation Type Inhibition

  Calcitriol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Calcitriol increases the expression of SLC10A2 [2]

  Secretin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Secretin induces the activity of SLC10A2 [3]

  Budesonide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Budesonide induces the activity of SLC10A2 [4]

  Dexamethasone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dexamethasone induces the activity of SLC10A2 [4]

  Ciprofibrate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ciprofibrate induces the activity of SLC10A2 [5]

  Irbesartan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Irbesartan inhibits the activity of SLC10A2 [6]

Drug in Phase 3 Trial

  Resveratrol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Resveratrol inhibits the expression of SLC10A2 [8]

  Elobixibat

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Elobixibat inhibits the activity of SLC10A2 [12]

Drug in Phase 2 Trial

  LUM001

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 LUM001 inhibits the activity of SLC10A2 [10]

  GSK2330672

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 GSK2330672 modulates the activity of SLC10A2 [11]

  264W94

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 264W94 modulates the activity of SLC10A2 [13]

  S-8921

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 S-8921 inhibits the activity of SLC10A2 [14]

  Colestyramine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Colestyramine induces the activity of SLC10A2 [16]

Drug in Phase 1/2 Trial

  Taurocholic Acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Taurocholic acid modulates the activity of SLC10A2 [1]

Drug in Phase 1 Trial

  GSK1614235 + GSK2330672

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 GSK1614235 + GSK2330672 modulates the activity of SLC10A2 [15]

Investigative Drug

  Taurochenodeoxycholate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Taurochenodeoxycholate inhibits the transportation of Sodium taurocholate by SLC10A2 (Ki = 6.1 microM) [1]

Affected Drug/Substrate

 Sodium taurocholate Modulation Type Inhibition

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)1-ASBT

  Tauroursodeoxycholate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tauroursodeoxycholate inhibits the transportation of Sodium taurocholate by SLC10A2 (Ki = 28 microM) [1]

Affected Drug/Substrate

 Sodium taurocholate Modulation Type Inhibition

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)1-ASBT

Mycotoxins

  Deoxynivalenol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Deoxynivalenol inhibits the expression of SLC10A2 [9]

Carcinogen

  Benzo(a)pyrene

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Benzo(a)pyrene increases the expression of SLC10A2 [7]
References
1 Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am J Physiol. 1998 Jan;274(1 Pt 1):G157-69.
2 Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
3 Secretin activation of the apical Na+-dependent bile acid transporter is associated with cholehepatic shunting in rats. Hepatology. 2005 May;41(5):1037-45.
4 Human ileal bile acid transporter gene ASBT (SLC10A2) is transactivated by the glucocorticoid receptor. Gut. 2004 Jan;53(1):78-84.
5 Human apical sodium-dependent bile salt transporter gene (SLC10A2) is regulated by the peroxisome proliferator-activated receptor alpha. J Biol Chem. 2002 Aug 23;277(34):30559-66.
6 Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP). Mol Pharm. 2013 Mar 4;10(3):1008-19.
7 Benzo[a]pyrene-induced changes in microRNA-mRNA networks. Chem Res Toxicol. 2012 Apr 16;25(4):838-49.
8 Resveratrol promotes degradation of the human bile acid transporter ASBT (SLC10A2). Biochem J. 2014 Apr 15;459(2):301-12.
9 Exposure to the mycotoxin deoxynivalenol reduces the transport of conjugated bile acids by intestinal Caco-2 cells. Arch Toxicol. 2022 May;96(5):1473-1482.
10 Current research on the treatment of primary sclerosing cholangitis. Intractable Rare Dis Res. 2015 Feb; 4(1): 1-6.
11 Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes. J Med Chem. 2013 Jun 27;56(12):5094-114.
12 Elobixibat for the treatment of constipation. Expert Opin Investig Drugs. 2013 Feb;22(2):277-84.
13 Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes. Am J Physiol Endocrinol Metab. 2012 Jan 1;302(1):E68-76.
14 Inhibition of ileal Na+/bile acid cotransporter by S-8921 reduces serum cholesterol and prevents atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol. 1998 Aug;18(8):1304-11.
15 Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 960).
16 Coordinate regulation of bile acid biosynthetic and recovery pathways. Biochem Biophys Res Commun. 1996 Aug 5;225(1):128-33.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.